Physician profile
Joseph J Murphy
NPI 1093781148
$2,408.92
in general payments reported to CMS, 2019-2025
28 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.53 · 2020: $40.76 · 2021: $13.52 · 2022: $276 · 2023: $1,024 · 2024: $719 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,064.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caldera Medical, INC | $444.75 | 2023-2024 | Desara |
| Abbvie INC. | $362.19 | 2021-2025 | |
| Myriad Women'S Health, INC. | $201.90 | 2023 | Myrisk |
| Sumitomo Pharma America, INC. | $175.12 | 2023-2025 | Myfembree, Gemtesa |
| Coopersurgical, INC. | $166.57 | 2023-2025 | Mara Console, Paragard T 380a, Summit Doppler |
| Mayne Pharma Commercial LLC | $142.31 | 2022-2025 | |
| Exeltis, USA INC. | $134.94 | 2022-2025 | Slynd |
| Organon LLC | $93.23 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.24 | 2022-2023 | |
| Daiichi Sankyo INC. | $72.85 | 2023-2025 | Injectafer |
| Medtronic, INC. | $64.34 | 2022-2023 | Truclear |
| Hologic Sales and Service, LLC | $63.12 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Sage Therapeutics, LLC | $62.24 | 2024-2025 | Zurzuvae |
| Channel Medsystems, INC. | $47.35 | 2022-2023 | |
| Meditrina | $35.56 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $25.46 | 2024 | Perclot |
| Ethicon US, LLC | $25.38 | 2024 | Enseal |
| Eisai INC. | $24.03 | 2020 | |
| Astellas Pharma US INC | $22.92 | 2025 | Veozah |
| Shield Therapeutics INC | $19.32 | 2023 | Accrufer |
| Therapeuticsmd, INC. | $18.58 | 2022 | |
| Biogen, INC. | $18.36 | 2023 | Spinraza |
| Duchesnay USA Incorporated | $18.03 | 2022 | |
| Glaxosmithkline, LLC. | $17.66 | 2023 | Shingrix, Trelegy Ellipta |
| Covidien LP | $16.73 | 2020 | |
| Pfizer INC. | $15.95 | 2023 | |
| Amgen INC. | $14.53 | 2019 | |
| Urovant Sciences INC | $14.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.